Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Inflationary Headwinds, Chinese CRO WuXi PharmaTech Set To Ride Wave Of Global Outsourcing

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Leading Chinese contract research organization WuXi PharmaTech will face inflationary pressure on profits this year, but stepped-up outsourcing of research to China by international pharmaceutical players and the Shanghai-based firm's expanding range of services are likely to ensure strong earnings through 2011 and beyond, according to a prominent analyst who monitors the country's healthcare sector

You may also be interested in...



The Rise Of The Chinese CRO: New Models For An Emerging Player

SHANGHAI - Shrinking margins are adding pressure to contract research organizations in the U.S., and on the other side of the globe, CROs in China are facing the same problem, due to higher labor costs and appreciation of the RMB. Led by WuXi AppTec Inc., the largest Chinese CRO, local CROs are expanding services by entering into new partnering models with multinational clients and preparing for increasing domestic demands

The Rise Of The Chinese CRO: New Models For An Emerging Player

SHANGHAI - Shrinking margins are adding pressure to contract research organizations in the U.S., and on the other side of the globe, CROs in China are facing the same problem, due to higher labor costs and appreciation of the RMB. Led by WuXi AppTec Inc., the largest Chinese CRO, local CROs are expanding services by entering into new partnering models with multinational clients and preparing for increasing domestic demands

Vertex And Merck Neck-To-Neck In HCV Race

Vertex gets priority review for its protease inhibitor weeks after Merck announces its own accelerated timeline.

Related Content

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel